Publications by authors named "V Dacco"
Purpose: The study evaluated the effects of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in people with cystic fibrosis (pwCF) and a clinical history of Aspergillus fumigatus (AF) infection.
Methods: This prospective cohort study included pwCF who initiated ETI therapy and had received antifungal treatment in the preceding five years due to allergic bronchopulmonary aspergillosis (ABPA group) or other AF-related clinical manifestations (AF group). A control group of pwCF with no prior respiratory cultures positive for AF was also included.
Article Synopsis
- The study examines the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in improving lung function in people with cystic fibrosis (pwCF), specifically looking at the lung clearance index (LCI) as a sensitive measure.
- 129 pwCF, aged 12-36, were assessed at the start of ETI and after 6 and 12 months, revealing that while most showed significant improvement in lung function measurements (FEV), a small group did not (15.5% had no significant change).
- Those with minimal change in FEV had better initial pulmonary function, yet showed improved LCI values post-treatment, highlighting the LCI's role in evaluating ETI effectiveness
The introduction of CFTR modulator drugs like elexacaftor-tezacaftor-ivacaftor (ETI) has transformed the management of cystic fibrosis (CF), significantly improving symptoms, lung function, and quality of life, while reducing reliance on intravenous antibiotics. However, respiratory exacerbations in the CFTR modulators era remain poorly understood from both pathophysiological and clinical perspectives. We present the case of a 20-year-old Caucasian woman with CF (F508del/L1077P) who, after three years of ETI treatment, experienced a severe episode of hemoptysis, despite being almost asymptomatic in the weeks leading up to admission, requiring bronchial artery embolization.
View Article and Find Full Text PDFObjective: The objective of this study was to describe reported adverse events (AEs) associated with elexacaftor/tezacaftor/ivacaftor (ETI) in a pediatric sample with cystic fibrosis (CF) aged 6-18 years, with at least one F508del variant, followed at multiple Italian CF centers.
Study Design: This was a retrospective, multicenter, observational study. All children receiving ETI therapy from October 2019 to December 2023 were included.